Spark Therapeutics Inc Quick Ratio (ONCE) starting from the third quarter 2019 to third quarter 2018, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Spark Therapeutics Inc   (NASDAQ: ONCE)

Spark Therapeutics Inc 's Quick Ratio

ONCE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2019, Quick Ratio fell to 3.89 a new company low.

Within Biotechnology & Pharmaceuticals industry 70 other companies have achieved higher Quick Ratio than Spark Therapeutics Inc in third quarter 2019. While Quick Ratio total ranking in the third quarter 2019 has deteriorated compared to the prior quarter from 601 to 866.

Explain Quick Ratio?
How much Cash & cash equivalents ONCE´s has?
What are ONCE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ONCE Quick Ratio (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1		 (Dec 31 2018)
Q4		 (Sep 30 2018)
Q3
Y / Y Current Liabilities Change 69.08 % 141.48 % 58.2 % 49.47 % 91.54 %
Y / Y Cash & cash equivalent Change -33.97 % -38.07 % -28.72 % -12.8 % 23.35 %
Quick Ratio MRQ 3.89 4.43 4.84 7.27 9.95
ONCE's Total Ranking # 866 # 601 # 532 # 340 # 128
Seq. Current Liabilities Change 10.95 % 4.59 % 38.62 % 5.12 % 58.45 %
Seq. Cash & cash equivalent Change -2.73 % -4.29 % -7.68 % -23.18 % -8.77 %



Quick Ratio third quarter 2019 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 71
Healthcare Sector # 407
Overall Market # 866


Quick Ratio Statistics
High Average Low
21 11.03 3.89
(Mar 31 2015)   (Sep 30 2019)




Financial Statements
Spark Therapeutics Inc 's Current Liabilities $ 100 Millions Visit ONCE's Balance sheet
Spark Therapeutics Inc 's Cash & cash equivalent $ 390 Millions Visit ONCE's Balance sheet
Source of ONCE's Sales Visit ONCE's Sales by Geography


Cumulative Spark Therapeutics Inc 's Quick Ratio

ONCE's Quick Ratio for the trailling 12 Months

ONCE Quick Ratio

 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months		 (Dec 31 2018)
12 Months		 (Sep 30 2018)
12 Months
Y / Y Current Liabilities TTM Growth 75.8 % 81.18 % 49.29 % 53.14 % 51.04 %
Y / Y Cash & cash equivalent TTM Growth -29.09 % -16.56 % 17.08 % 55.2 % 88.48 %
Quick Ratio TTM 4.9 6.24 8.59 10.66 12.15
Total Ranking TTM # 4325 # 386 # 140 # 125 # 163
Seq. Current Liabilities TTM Growth 13.73 % 21.57 % 14.88 % 10.69 % 17.21 %
Seq. Cash & cash equivalent TTM Growth -10.76 % -11.68 % -7.41 % -2.84 % 5 %

Quick ratio ranking by company, industry and sector >> Back to ONCE Financial Strength Comparisons >> Go to Compare ONCE Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2019 to $100.30 millions, cumulative Quick Ratio decreased to 4.9 below the Spark Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 104 other companies have achieved higher Quick Ratio than Spark Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2019 from 386 to 4325.

Explain Quick Ratio?
How much Cash & cash equivalents ONCE´s has?
What are ONCE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 105
Healthcare Sector # 858
Within the Market # 4325


trailing twelve months Quick Ratio Statistics
High Average Low
14.75 10.8 4.9
(Dec 31 2015)   (Sep 30 2019)




Companies with similar Quick Ratio in the quarter ending Sep 30 2019, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2019 MRQ Cash & cash equivalentSep 30 2019 MRQ Current Liabilities
Regenxbio Inc   10.58 $ 331.719  Millions$ 31.345  Millions
X4 Pharmaceuticals Inc  10.30 $ 76.251  Millions$ 7.401  Millions
Denali Therapeutics Inc   10.27 $ 479.390  Millions$ 46.685  Millions
Vivosim Labs Inc   9.72 $ 30.350  Millions$ 3.122  Millions
Atara Biotherapeutics Inc   9.21 $ 282.922  Millions$ 30.706  Millions
Replimune Group Inc   9.17 $ 109.879  Millions$ 11.982  Millions
Adverum Biotechnologies Inc   9.13 $ 161.985  Millions$ 17.746  Millions
Precision Biosciences Inc  8.69 $ 206.265  Millions$ 23.726  Millions
Ladrx Corporation  8.43 $ 18.515  Millions$ 2.196  Millions
Kodiak Sciences Inc   8.30 $ 60.604  Millions$ 7.301  Millions
Crispr Therapeutics Ag  7.89 $ 629.717  Millions$ 79.779  Millions
Applied Genetic Technologies Corporation  7.72 $ 71.111  Millions$ 9.210  Millions
Vir Biotechnology Inc   7.42 $ 329.032  Millions$ 44.316  Millions
Surface Oncology Inc   7.18 $ 111.804  Millions$ 15.573  Millions
Lineage Cell Therapeutics Inc   7.10 $ 35.684  Millions$ 5.024  Millions
Eiger Biopharmaceuticals Inc   6.75 $ 109.951  Millions$ 16.279  Millions
Momenta Pharmaceuticals inc   6.70 $ 271.730  Millions$ 40.581  Millions
Curis Inc   6.54 $ 28.162  Millions$ 4.309  Millions
Gritstone Bio Inc   6.53 $ 149.465  Millions$ 22.893  Millions
Alector Inc   6.50 $ 381.446  Millions$ 58.718  Millions
Meiragtx Holdings Plc  6.47 $ 254.170  Millions$ 39.290  Millions
Compugen Ltd  6.43 $ 43.879  Millions$ 6.819  Millions
Genfit S a   6.34 $ 309.958  Millions$ 48.896  Millions
Solid Biosciences Inc   6.31 $ 105.663  Millions$ 16.750  Millions
Fate Therapeutics Inc   6.15 $ 249.588  Millions$ 40.595  Millions
Bluebird Bio Inc   6.02 $ 1,179.955  Millions$ 196.031  Millions
Protara Therapeutics Inc  5.80 $ 9.349  Millions$ 1.613  Millions
Neurocrine Biosciences Inc   5.79 $ 670.162  Millions$ 115.652  Millions
Eloxx Pharmaceuticals Inc   5.78 $ 64.936  Millions$ 11.227  Millions
Aptose Biosciences Inc   5.71 $ 19.379  Millions$ 3.395  Millions

Date modified: 2026-09-08T15:09:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.